AR121093A1 - Compuestos coagonistas de gip / glp1 - Google Patents

Compuestos coagonistas de gip / glp1

Info

Publication number
AR121093A1
AR121093A1 ARP210100135A ARP210100135A AR121093A1 AR 121093 A1 AR121093 A1 AR 121093A1 AR P210100135 A ARP210100135 A AR P210100135A AR P210100135 A ARP210100135 A AR P210100135A AR 121093 A1 AR121093 A1 AR 121093A1
Authority
AR
Argentina
Prior art keywords
compounds
gip
coagonist
glp1
receptors
Prior art date
Application number
ARP210100135A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Robert Andrew Brown
Robert Chadwick Cummins
Mohammed Elsayed Hamed Elsayed
Andrea Renee Geiser
Xianyin Lai
Hongchang Qu
Brian Morgan Watson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR121093A1 publication Critical patent/AR121093A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se refiere a compuestos que tienen actividad tanto en los receptores de polipéptido insulinotrópico dependiente de glucosa humana (GIP) como de péptido 1 similar a glucagón (GLP-1). La presente también se refiere a compuestos que tienen duración de acción prolongada en cada uno de estos receptores. Además, la presente se refiere a compuestos que se pueden administrar oralmente. Los compuestos pueden ser útiles en el tratamiento de diabetes mellitus tipo 2 (“T2DM”). Los compuestos pueden ser útiles en el tratamiento de obesidad.
ARP210100135A 2020-01-23 2021-01-21 Compuestos coagonistas de gip / glp1 AR121093A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062964932P 2020-01-23 2020-01-23

Publications (1)

Publication Number Publication Date
AR121093A1 true AR121093A1 (es) 2022-04-20

Family

ID=74592824

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100135A AR121093A1 (es) 2020-01-23 2021-01-21 Compuestos coagonistas de gip / glp1

Country Status (13)

Country Link
US (1) US20230265151A1 (es)
EP (1) EP4093757A1 (es)
JP (1) JP2023511441A (es)
KR (1) KR20220131292A (es)
CN (1) CN115298207A (es)
AR (1) AR121093A1 (es)
AU (1) AU2021211451B2 (es)
BR (1) BR112022014397A2 (es)
CA (1) CA3165430A1 (es)
IL (1) IL294955A (es)
MX (1) MX2022009149A (es)
TW (1) TWI770781B (es)
WO (1) WO2021150673A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022177744A1 (en) * 2021-02-17 2022-08-25 Eli Lilly And Company Gip/glp1 dual agonist therapeutic methods
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
CN116023444B (zh) * 2022-08-12 2023-08-01 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2718317B1 (en) * 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
NZ702333A (en) * 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
RU2652783C2 (ru) * 2012-12-21 2018-05-03 Санофи Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона
CN105849122B (zh) * 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
AR104932A1 (es) * 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
CA3165430A1 (en) 2021-07-29
IL294955A (en) 2022-09-01
CN115298207A (zh) 2022-11-04
US20230265151A1 (en) 2023-08-24
TWI770781B (zh) 2022-07-11
KR20220131292A (ko) 2022-09-27
JP2023511441A (ja) 2023-03-17
WO2021150673A1 (en) 2021-07-29
BR112022014397A2 (pt) 2022-10-11
EP4093757A1 (en) 2022-11-30
MX2022009149A (es) 2022-12-15
AU2021211451A1 (en) 2022-08-18
TW202140528A (zh) 2021-11-01
AU2021211451B2 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
ECSP21004913A (es) Compuestos coagonistas de gip/glp1
AR121093A1 (es) Compuestos coagonistas de gip / glp1
AR119471A1 (es) Compuestos agonistas de gipr
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
AR084558A1 (es) Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
BR112021020071A2 (pt) Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
EA201370099A1 (ru) Терапия на основе лигандов хемосенсорных рецепторов
EA201590759A1 (ru) Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина
JP2014504588A5 (es)
BR112022023834A2 (pt) Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo
BR112023003668A2 (pt) Agonistas duplos de glp-1/gip
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
DOP2022000122A (es) Analogos de incretina y sus usos
CL2023000090A1 (es) Coagonistas de los receptores de glp-1 y gip
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
CO2023012373A2 (es) Composiciones que contienen análogos de incretina y usos de estas
EA202192296A1 (ru) Терапевтическое применение дулаглутида
AR123039A1 (es) Coagonistas de los receptores de glp-1 y gip
BR112023024968A2 (pt) Tratamento da obesidade e distúrbios relacionados à obesidade